Clinical Trials Browser

Cervical Esophagus Adenocarcinoma

NCT06576037 2026-04-16

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

Phase 1 Recruiting

128 enrolled

Other solid neoplasm

Solid Tumor

NCT07532902 2026-04-16

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

Phase 1 Recruiting

60 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT02143219 2026-04-15

PAMELA70

Phase 2 Completed

72 enrolled 7 charts

Gastrointestinal

Pancreatic Metastatic Cancer

NCT04481204 2026-04-15

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Phase 2 Active not recruiting

105 enrolled

Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

NCT03406299 2026-04-09

Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer

Phase 2 Completed

92 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT04745988 2026-04-09

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

Phase 2 Active not recruiting

43 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05567835 2026-04-09

TOGAR

Phase 2 Terminated

3 enrolled

Gastrointestinal

Stomach Neoplasms

NCT06958328 2026-04-08

LAP100

Phase 3 Recruiting

356 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT03764553 2026-04-07

LyRICX

Phase 2 Active not recruiting

320 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT05677490 2026-04-07

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Phase 3 Recruiting

382 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT07283939 2026-04-07

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

Phase NA Recruiting

420 enrolled

Gastrointestinal

Appendiceal Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Rectal Neoplasms, Stomach Neoplasms

NCT03801876 2026-04-03

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

Phase 3 Recruiting

300 enrolled

Gastrointestinal

Clinical Stage I Esophageal Adenocarcinoma AJCC v8

NCT04245865 2026-04-03

Toco-CoR

Phase 2 Active not recruiting

83 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06483555 2026-04-01

PANGEA

Phase 1/2 Recruiting

104 enrolled

DermatologicGastrointestinal

Pancreatic Neoplasms, Neoplasms, Basal Cell

NCT02366819 2026-03-30

Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Phase 4 Suspended

36 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT04703101 2026-03-30

Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

Phase 1 Recruiting

25 enrolled

Gastrointestinal

Rectal Neoplasms

NCT06538623 2026-03-24

Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer

Phase 2 Completed

40 enrolled

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

Clinical Trials

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

PAMELA70

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

TOGAR

LAP100

LyRICX

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

Toco-CoR

PANGEA

Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer